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Abstract: Background: Platelet-rich plasma (PRP) is an autologous blood product that contains
a high concentration of platelets and leucocytes, which are fundamental fibroblast proliferation
agents. Literature has emerged that offers contradictory findings about leucocytes within PRP.
Herein, we elucidated the effects of highly concentrated leucocytes and platelets on human fibroblasts.
Methods: Leucocyte-rich, PRP (LR-PRP) and leucocyte-poor, platelet-poor plasma (LP-PPP) were
compared to identify their effects on human fibroblasts, including cell proliferation, wound healing
and extracellular matrix and adhesion molecule gene expressions. Results: The LR-PRP exhibited
1422.00 ± 317.21 × 103 platelets/µL and 16.36 ± 2.08 × 103 white blood cells/µL whilst the LP-PPP
demonstrated lower concentrations of 55.33 ± 10.13 × 103 platelets/µL and 0.8 ± 0.02 × 103 white blood
cells/µL. LR-PRP enhanced fibroblast cell proliferation and cell migration, and demonstrated either
upregulation or down-regulation gene expression profile of the extracellular matrix and adhesion
molecules. Conclusion: LR-PRP has a continuous stimulatory anabolic and ergogenic effect on human
fibroblast cells.
Keywords: platelet-rich plasma; PRP; platelet gel; platelet-rich fibrin; fibroblasts; extracellular matrix;
leucocytes; wound
1. Introduction
Platelet-rich plasma (PRP) has gained encouraging recognition as an accepted protocol for
treating injuries; however, research has mainly focused on orthobiologic applications with few
studies being performed on fibroblasts and their relation to cutaneous delayed wound healing [1–6].
Overcoming delayed wound healing has generated a need to incorporate novel therapies such as
PRP [7,8]. PRP involves the preparation of autologous and biologically safe blood products that contain
concentrated leucocytes and platelets, which releases growth factors, cytokines and chemokines and
subsequently influences tissue regenerative cells such as fibroblasts [9,10]. However, the leucocytes
within PRP have gained recent adverse attention [11,12] with an emphasis on their contribution
to inflammation and premature apoptosis. Therefore, some researchers consider leucocyte-rich,
platelet-rich plasma (LR-PRP) to be potentially harmful to tissue regeneration [13–15]. This study
engaged in three in vitro experiments to elucidate the effects of LR-PRP on challenged fibroblasts,
as follows: (i) fibroblast proliferation assay; (ii) scratch wound assay; and (iii) the human extracellular
matrix (ECM) and adhesion molecules RT2 Profiler PCR gene array.
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The LR-PRP is obtained by density gradient centrifugation of whole blood, which separates
the plasma, leucocytes and platelets from the red blood cells (RBCs) to form a buffy coat.
The buffy coat is resuspended into a small amount of plasma to form the final LR-PRP product.
Leucocyte-poor, platelet-poor plasma (LP-PPP) is the residual plasma once the LR-PRP is extracted [16].
Plasma subsequently conserves and transports platelets, leucocytes and nutrients [17,18]. The leucocytic
fraction of PRP is often uncharacterized with the imprecise umbrella term “leucocyte-rich”
employed [19]. For clarity, this study defines LR-PRP as containing a white blood cell (WBC)
concentration greater than 100% of that of whole blood and LP-PRP as containing a WBC concentration
less than 100% of that of whole blood [11]. In order to simulate a fibroblast in the edges of a chronic
wound the fibroblasts were deprived of nutrients by being placed in serum-free media. Under these
conditions, fibroblasts conserve energy and cease proliferation [20–22]. The challenged fibroblasts
were supplemented with LR-PRP and LP-PPP, and the effects were evaluated.
Fibroblasts were chosen as the experimental cells in this study due to their critical role
in wound healing [23,24]. Effective wound healing relies on fibroblast differentiation into
myofibroblasts, and collagen type I and III fibril accumulation [25]. In compromised wound
healing, collagen fibrils fragment, inhibiting fibroblasts interactions, wound contraction and ECM
remodelling [7,23,26]. The ECM is a three-dimensional multi-molecular network that defines a
tissue’s shape, structure and functions. ECM remodelling is mediated by an elaborate network of
proteinases (e.g., matrix metallopeptidase [MMP]) and adhesion proteins, which are secreted from
stromal cells, such as fibroblasts, epithelial and endothelial cells. MMPs are by-products of fibroblasts,
macrophages, and migrating keratinocytes that modulate cell surface receptors, cell signalling,
cell death, inflammation and will spontaneously inactivate once the wound has closed [27,28].
Moreover, MMPs disassemble an impaired ECM, regulate extracellular tissue signalling networks,
and induce angiogenesis and immune responses [29]. Alternatively, adhesion molecules facilitate the
reassembly of the ECM via cell-to-cell and cell-to-ECM cross-talk [30]. Cell adhesion molecule include
the integrins (ITGs), selectins, intercellular adhesion molecules (ICAM), neural cell adhesion molecules
(NCAM), vascular cell adhesion molecules (VCAM), and the catenins [30,31]. These molecules,
in conjunction with growth factors and leucocytes, generate an ideally organised ECM infrastructure,
which synchronises cell growth and optimises wound healing [32–34].
Tissue regeneration in wounds relies on leucocytes [8]. Some of the monocytes in wounds polarize
into anti-inflammatory and reparative M2 macrophages [35–38]. Additionally, platelets release a
multitude of growth factors, such as platelet derived growth factor, vascular endothelial growth factor
and transforming growth factor (TGF-β) [39,40], the latter promoting fibroblast proliferation and
recruitment to the wound bed [41,42]. Consequently, LR-PRP which contains both WBCs and platelets,
probably could serve as a complementary treatment for delayed woundhealing.
2. Results
2.1. Haematological Values: Whole Blood, LR-PRP and LP-PPP
The haematological data for the whole blood, LR-PRP and LP-PPP used are available in Supplementary
Materials (Table S1). Haematocrit percentages of the initial collected blood, LR-PRP and LP-PPP volume
were calculated by applying the formulae that are available in Supplementary Materials (Table S2) [18,43].
2.2. LR-PRP and LP-PPP Enhance Proliferation of Fibroblast Cells
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, a tetrazole) (MTT) assay was
performed to evaluate the influence of LR-PRP and LP-PPP on fibroblast proliferation at 4, 8, 12, 24 and
48 h (h) time points (Figure 1). At 4 h, LR-PRP proliferation was significantly higher than the negative
control (** p = 0.003). At 8 h LP-PPP proliferation was significantly increased compared to the negative
control (* p = 0.024). At 12 h, LR-PRP proliferation was highly significantly different in comparison to the
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negative control (*** p < 0.001). The 12 h was the elected time period for the analysis of the expression of
mRNA genes of human ECM and adhesion molecule for this study.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 3 of 16 
 
Figure 1. MTT Fibroblast Proliferation Assay. LR-PRP, LP-PPP, serum-free media (negative control) 
measured at 5 time points 4, 8, 12, 24, 48 hours. Data were analyzed and the means for n = 3 samples 
(6 replicate wells for each sample) were calculated and presented as plus or minus (±) the standard 
error of the mean (SEM) using a two-way ANOVA and Tukey’s multiple comparison tests.  Symbols 
represent the p value; * p < 0.024 significant difference, ** p < 0.003 very significant difference, *** p < 
0.001 highly significant difference. Abbreviations: Leucocyte-rich, platelet-rich plasma (LR-PRP),  
leucocyte-poor, platelet poor plasma (LP-PPP). 
2.3. LR-PRP and LP-PPP Enhance Fibroblast Migration in Wound Scratch Assay 
LR-PRP and LP-PPP were applied to challenged fibroblasts to assess their effects on migration, 
via an in vitro scratch wound assay. The migration rate was measured by the shortest wound edge 
distance of each scratch. The fibroblast cell monolayer migration for wound closure time and 
migration rate (nm/h) were calculated. At time 8 h and 12 h, there were no significant difference in 
wound closure compared to the negative control. At the 24 h time point LR-PRP showed 
approximately 50% wound closure and was significantly increased compared to the LP-PPP (* p = 
0.033). Wells supplemented with LR-PRP achieved 100% wound closure at 48 h (*** p < 0.001), with a 
migration rate of 20 nm/h. Fibroblast wells supplemented with LP-PPP demonstrated a 60.1% wound 
closure and a migration rate of 12 nm/h which was similar to the negative control of 63.1% at a rate 
of 7.3 nm/h at 48 h (Figure 2).  
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the p value; * p < 0.024 significant difference, ** p < 0.003 very significant difference, *** p < 0.001 highly
significant difference. Abbreviations: Leucocyte-rich, platelet-rich plasma (LR-PRP), leucocyte-poor,
platelet poor plasma (LP-PPP).
2.3. LR-PRP and LP-P P Enhance i tion in ound Scratch Assay
LR-PRP and LP-P P were a lie to c allenged fibroblasts to assess their effects on migration,
via an in vitro scratch wound assay. The igration rate was measured by the shortest wound edge
distance of each scratch. The fibroblast cell monolayer migration for wound closure time and migration
rate (nm/h) were calculated. At time 8 h and 12 h, there were no significant difference in wound closure
compared to the negative control. At the 24 h time point LR-PRP showed approximately 50% wound
closure and was significantly increased compared to the LP-PPP (* p = 0.033). Wells supplemented
with LR-PRP achieved 100% wound closure at 48 h (*** p < 0.001), with a migration rate of 20 nm/h.
Fibroblast wells supplemented with LP-PPP demonstrated a 60.1% wound closure and a migration rate
of 12 nm/h which was similar to the negative control of 63.1% at a rate of 7.3 nm/h at 48 h (Figure 2).
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Figure 2. Scratch wound assay. Wound closure for each time point and group is measured in
percentages. Data were analyzed for n = 3 samples (6 replicate wells for each sample) using the
mean ± standard error of the mean (SEM) using a two-way ANOVA and Tukey’s multiple comparison tests
(* p = 0.033 statistically significant difference, *** p < 0.001 very highly statistically significant difference).
Abbreviations: Leucocyte-rich-platelet-rich plasma (LR-PRP), leucocyte-poor-platelet poor plasma (LP-PPP),
negative control (NC).
2.4. Expression of mRNA Genes of Human ECM and Adhesion Molecules
QIAseq targeted RNA virtual panels were used, in which 84 genes that encode human ECM
and adhesion proteins were evaluated. The sample management consisted of LR-PRP versus LP-PPP
(control) (Figure 3A), and LR-PRP versus serum-free media (negative control) (Figure 3B). The RNA
concentrations and purity were determined by measuring the absorbance by spectrophotometry
(Nanodrop, Denovix). The results demonstrated the 260/280 nm and 260/230nm measurements were
>1.8 and therefore all samples met the criterion. The RNA integrity number (RIN) was measured via a
bioanalyzer (Agilent) in which >7.4 was required for reliable data. In this experiment, the RIN achieved
was between 9.3 and 9.7. There was no smearing of the RNA bands, indicating no RNA sample
degradation. Furthermore, conforming to the Qiagen software, all fold-changes equal or greater than 2
indicated gene up-regulation. Fold-changes equal or less than minus 2 indicates gene down-regulation.
Notably, 13 gene expressions with significant variances were identified in the LR-PRP and LP-PPP
test groups. The genes were labelled by their approved symbols [44], which are numerically classified
according to their substrate specificities [45–47]. The PCR results for the LR-PRP versus LP-PPP (control)
exhibited an up-regulated expression of seven genes: MMP1, MMP3, MMP9, MMP12, ITGA2, ITGA6
and TIMP3. Simultaneously, the down-regulation of six genes occurred such as VCAM1, NCAM1,
ITGA8, ITGB4, MMP11 and ITGAM, which is displayed in Figure 3A. In the LR-PRP versus serum-free
media (negative control), the up- regulated expression of five genes occurred: namely MMP1, MMP3,
MMP9, MMP12, and ITGA2; in addition to the down-regulation of MMP11, ITGB4, and ITGAM which
is displayed in Figure 3B. The LP-PPP sample versus serum-free media (negative control) exhibited the
up-regulation of only ITGA8. All 84 genes of human ECM and adhesion molecules are described in
Supplementary Materials (Figure S1).
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Figure 3. The human extracellular matrix and adhesion molecules RT2 Profiler PCR gene array. Fibroblasts
supplemented with (A) LR-PRP versus LP-PPP (control) at 12 h or (B) LR-PRP versus serum-free media
(negative control) representing significant up- and down-regulated genes (more than two-fold) and those with
no significant change (less than two-fold). Abbreviations: MMP1, matrix metallopeptidase 1 (collagenase);
MMP3, matrix metallopeptidase 3 (stromelysin); MMP9, matrix metallopeptidase 9 (gelatinase); MMP11,
matrix metallopeptidase 11 (stromelysin); MMP12, matrix metallopeptidase 12 (metalloelastase); ITGA2,
integrin alpha 2; ITGA6, integrin, alpha 6; ITGA8, integrin alpha 8; ITGAM, integrin alpha M chain; ITGB4,
integrin beta 4; TIMP3, metalloproteinase inhibitor 3; NCAM1, neural cell adhesion molecule 1; VCAM1,
vascular cell adhesion molecule 1, leucocyte-rich—platelet-rich plasma (LR-PRP), leucocyte-poor—platelet
poor plasma (LP-PPP). Letter A specifies that the gene’s average threshold cycle is relatively high (>30) in
either the control or the test sample and is reasonably low in the other sample (<30). These data mean
that the gene’s expression is relatively low in one sample and reasonably detected in the other sample,
which suggests that the actual fold-change value is at least as large as the calculated and reported fold-change
result. Letter B specifies that the gene’s average threshold cycle is relatively high (>30), meaning that its
relative expression level is low, in both control and test samples, and the p value for the fold-change is either
unavailable or relatively high (p > 0.05).
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3. Discussion
Each of the components in PRP preparations confers specific biologic properties. In clinical and
laboratory settings, PRP point-of-care devices vary from commonplace laboratory tubes to highly
advanced, automated cell separating apparatuses. The efficiency of platelet recovery fluctuates between
systems and subsequently not all PRP formulations are equal [48]. The problem is compounded when
publications have not included PRP composition data [42,49–51]. To avoid these ambiguities, this study
implemented the DEPA classification method to characterize the LR-PRP and LP-PPP [18]. The DEPA
classification includes four parameters: dose of platelets; efficiency of PRP production; the purity of
PRP, which refers to the relative composition of platelets, leucocytes and RBCs; and the activation
method used. Each of these parameters provides information that assists in the interpretation of
experimental data [9,52,53].
As reported in Table S1, the LR-PRP platelet yield and composition indicate high production
efficiency. Moreover, the platelet factor increase measure was high (8.75 ± 1.92). The purity was
also high as demonstrated by the low WBC and RBC composition of 1.19 ± 0.16% and 0.03 ± 0.01%
respectively. Determining the number of RBCs in each sample was important, as clinicians are
concerned about their release of reactive oxygen species and the subsequent adverse effects on tissue
cells [43,53,54]. The objective of this study was to evaluate the effects of LR-PRP and LP-PPP on human
fibroblast activities related to cutaneous wound healing therefore the WBC count was important.
The LR-PRP produced attained a white blood cell factor increase of 3.48 ± 0.45 and therefore its
designation as LR-PRP was confirmed [11]. Hence, the LR-PRP data attained a DEPA score of AAA.
The effects of leucocytes in PRP has gained recent attention [11,12,55,56] with an emphasis on
their influence on inflammation and premature apoptosis [13–15]. However, leucocytes comprise only
approximately 0.1% to 1% of the final content of PRP. One study argued that LR-PRP may intensify
the over-expression of MMP and consequently activate ECM catabolic pathways and excessive
inflammation [57]. This concept was also accentuated in another study [15], which reported that
leucocytes in PRP initiated a greater activation of the nuclear factor kappa-light-chain-enhancer of
activated B cells pathway, and subsequently resulting in significantly less fibroblast proliferation and
a higher concentration of pro-inflammatory cytokines. However, this study’s PRP contained a high
concentration of RBCs and therefore could be the source of this reaction. Dohan Ehrenfest et.al [58]
demonstrated that LR-PRP generated a more sustainable fibrin matrix compared to leucocyte-poor
PRP, which directly challenges the previous findings [15]. To our knowledge, no clear evidence has
confirmed that leucocytes initiate catabolic pathways or that catabolic pathways are even related to
leucocyte concentrations. In fact, some studies have illustrated that leucocytes cause no adverse effects
and moreover have demonstrated that wound healing essentially relies upon immune-modulatory
mechanisms [3,14,59–62]. For instance, peripheral blood monocytes propagate pluripotent stem
cells, which are subsequently induced by the macrophage colony-stimulating factor. Monocytes also
transform into anti-fibrotic keratinocyte-like cells and therefore demonstrate regenerative effects [63–65].
Additionally, infection is a critical risk factor in chronic wounds, and therefore leucocytes introduced
into the wound, via LR-PRP, would exert an antimicrobial effect [66].
Clearly, the role of leucocytes within the wound milieu has not been fully elucidated. The aim of
this study’s three experiments was to explore the effect of leucocytes contained in LR-PRP on a key cell
that plays a central role in wound healing namely the fibroblast. In the proliferation experiment, the aim
was to determine the effects of LR-PRP on fibroblast which were challenged in serum-free media and
consequently ceased proliferation to conserve energy [21,22,67]. This assay identified the optimal
fibroblast RNA extraction time to be 12 h; however the time limit of 48 h was insufficient to produce
fibroblast proliferation data. For instance, previous studies allowed extended time frames of up to
7 days and subsequently only reaching significant proliferation at day 3 and 5 [68–71]. In the scratch
wound assay, LR-PRP achieved 100% closure within 48 h and also accomplished the greater speed of
20 nm/h compared with the LP-PPP of 12 nm/h and the negative control at 7.3 nm/h. According to
these data, we can positively propose that leucocytes, and likewise platelets, demonstrate a continuous
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stimulatory anabolic and ergogenic pathway in tissue repair, rather than a catabolic pathway as
proposed in some of the literature [15].
To our knowledge the human RT2 Profiler PCR gene array data provide one of the first studies into
LR-PRP and the human ECM and adhesion molecules such as transmembrane receptors, E-cadherin,
basement membrane constituents, collagen and ECM structural constituents, proteases and protease
inhibitors. The ECM is of a major interest in wound therapy because the outcome of the tissue’s
architecture and anatomical function is determined during the ECM turnover processes, thus its
disassembly and reassembly [72]. These ECM turnover processes are sustained via the facilitation of
proteolytic enzymes such as MMPs. MMPs are by-products of fibroblasts, macrophages, and migrating
keratinocytes that modulate cell surface receptors, cell–cell and cell–matrix signalling, cell death and
inflammation in wound healing and will spontaneously inactivate once the wound has closed [27].
This study confirmed the associations between MMPs and the ECM remodeling. For example,
the primary functions of MMP1, MMP3, MMP9 and MMP12 (up-regulated by LR-PRP) are to
orchestrate the disassembly and assembly of the ECM and subsequently provide a conduit for fibroblast
migration. In particular, up-regulated MMP1 degrades collagen type I and III and subsequently
facilitates progenitor cell migration. Conversely, the down-regulation of MMP1 may lead to keloid
and hypertrophic scarring [73,74]. Likewise, MMP3 degrades collagen types, I.I.; III, IV, IX and X;
proteoglycans; fibronectins; laminin; and elastin during the ECM remodeling phase. Additionally,
MMP3 regulates transcription and activation of pro-MMP (MMP1, MMP7 and MMP9), and thus,
collagenases, gelatinase B and matrilysin which facilitates ECM turnover. MMP9 activates and
inactivates cytokines and chemokines, recruits endothelial cells, and promotes angiogenesis [75],
whereas MMP12 disassembles the ECM and is significantly elastolytic [29,76]. These findings are
consistent with a similar study [27] which observed MMP1 up-regulation plus exhibited no cell inhibition
or cell death after PRP supplementation of fibroblasts. Our results are also in accordance with Cipriani
et al. [77] who noted increased expression of MMP9 in keratinocytes after PRP supplementation,
and demonstrated no cell inhibition or cell death. Likewise, our results agree with a study that
demonstrated MMP2, MMP3, and MMP9 up-regulation for up to 6 days in LR-PRP supplemented
cells [73]. In this study no cell inhibition or death occurred, which is likely attributed to the regulation
of MMP activity at the transcription and activation phases coordinated via the TIMP3’s (up-regulated
by LR-PRP) anti-inflammatory actions and subsequent inhibition of downstream signalling. Moreover,
TIMP3 minimizes the degree of remaining fibrotic tissue [29,78], and therefore coincides with the
down-regulation of MMP11 (in LR-PRP) which if up-regulated would cause excessive catabolic
processes and ageing fibroblasts [26]. According to these data, we infer that the MMPs expressed from
LR-PRP supplementation facilitates ECM disassembly, and subsequently provides the foundation for
the ECM reassembly.
In order to initiate ECM reassembly the cell adhesion molecules, such as integrins, facilitate the
anchoring of cells to the ECM through the binding of fibronectin, vitronectin and collagen [33].
Adhesion molecules provides a mechanical connection between the ECM and the cytoskeleton,
and functions as two-way signal-transducing receptors, linking the intracellular and extracellular
environments [79]. This enhances growth factor signalling by regulation of the number and
stability of receptor tyrosine kinases on the plasma membrane [80,81]. Additionally, directional
cell migration within wounds relies on integrin endocytosis and trafficking to coordinate the assembly
of new adhesions and their subsequent dissolution. Likewise, maximum cell migration speed is
determined by a medium strength cell adhesion, which is facilitated by integrin expressions and
ligand binding affinity [81]. The up-regulation of ITGA via the LR-PRP was demonstrated by the
enhanced directional cell migration and rate of speed in the wound scratch assay. Hence, the LR-PRP
achieved 100% wound closure and a significantly faster closure speed compared with the LP-PPP.
Moreover, LR-PRP up-regulated ITGA2, which initiates collagen synthesis, as well as regulating
inflammation and smooth muscle cell proliferation. This is coupled with the up-regulation of ITGA6
via LR-PRP, which promotes the recruitment of human mesenchymal stem cells to wounded tissue,
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and the assembly of hemidesmosomes in aide of keratinocyte migration [31]. Hence, ITGA6’s profound
mitogenic effect on stem cell proliferation could anticipate LR-PRP as a less expensive and lower
risk substitute to the harvesting of stem cells [82]. Moreover, ITGB4, which is down-regulated via
LR-PRP indicates the presence of fibroblast growth factors released from fibroblasts by the stimulation
of the LR-PRP. Conversely, if levels of ITGB4 are increased, which is abnormal and caused by a
variety of cellular insults, this causes a deprivation of growth factors and pro-apoptosis expression.
Hence, the LR-PRP exhibits a homeostatic fibroblast activity [83]. Additionally, in regular wound
healing, the ratio between ITGB4 and ITGA6 is instinctively balanced as a means to promote growth
factor optimization and moderate TGF-β signalling, which is critical for cutaneous regeneration [31].
As a response to wound stress, however, TGF-β will excite quiescent fibroblasts to differentiate
disproportionately into myofibroblasts, resulting in excessive ECM deposition and therefore fibrosis [84].
In the LP-PPP versus negative control, ITGA8 (responsible for TGF proliferation) was the sole
up-regulated gene with no accompanying down-regulated gene expressions [85]. The absence of
MMPs in this circumstance would ensure a compromised ECM turnover and subsequently precede
hypertrophic or keloid formation [86].
Although some studies proclaim that leucocytes generate catabolic pathways, leucocytes are
essentially fundamental to homeostasis especially by eliminating pathogenic and injurious stimuli [10].
For example, macrophages, T lymphocytes, and natural killer cells initiate immune responses via
tumor necrosis factor-α release, which subsequently stimulates VCAM1 and thus is down-regulated
via LR-PRP [87]. VCAM1 expresses on the membrane of activated endothelia in skin, regulates the
trans-endothelial migration of leucocytes and leucocyte-endothelial cell adhesion and mediates
immunoglobulin genes, mononuclear cells, eosinophils and vascular endothelium adhesion molecules.
The up-regulation of VCAM1 occurs in systemic oxidative stress, myeloperoxidase, autoimmune
disease and particularly in malignant melanoma. Hence, the down-regulation of VCAM1 via the
LR-PRP demonstrates homeostatic fibroblast activity [88,89]. Comparably, the leucocyte dependent
integrin gene, ITGAM, is down-regulated via the LR-PRP, which subsequently reduces leucocyte
adhesion and migration, and facilitates phagocytosis. The benefits of ITGAM down-regulation are
illustrated in the LR-PRP wound scratch assay, which restored the challenged fibroblasts to normal
activity, and no inhibition or cell death occurred. Finally, NCAM1 (down-regulated via LR-PRP)
primarily induces synaptic plasticity in the nervous system; however, it is also present in non-neural
tissues. NCAM1 facilitates fibroblast growth factor receptor signalling [90], cell-matrix adhesion,
cell migration and subsequently tissue regeneration [91,92]; however, when up-regulated NCAM1
serves as an immunohistochemical skin cancer marker [93,94].
Although there is a contrast in LR-PRP and LP-PPP cell concentrations, and it was expected
LR-PRP would be significant at all times, the LP-PPP too exhibited significant differences.
For instance, no significant changes of NCAM1 and VCAM1 occurred in the LR-PRP versus serum-free
(negative control), thus indicating LP-PPP possibly contributed to their enhancement. This result
may be explained by the fact that plasma, which contains albumins, globulins, fibrinogen, hormones,
electrolytes, glucose, gases and IGF-1, shares parallel importance to platelets and leucocytes in wound
healing [17]. Previous studies have shown plasma stimulates procollagen type 1, protein production
and MMP1 and MMP3 expressions; although the PRP was significantly higher [70,95]. The researcher’s
focus on platelet concentration efficacy in PRP overlooked the properties of plasma and may have
underestimated its value.
This study did not include in vivo experiments and therefore represents a scientific understanding
of LR-PRP in vitro. Subsequently these findings cannot be extrapolated directly into clinical applications
as each patient’s condition requires careful consideration. The scope of this study was focused
on the expression of genes after 12 h of incubation in order to determine the changes early on.
However, it would be of interest to determine gene expressions at different time points such as,
48, and 72 h, and to determine if these significant changes are transient or continuous between the
LR-PRP and LP-PPP. Likewise, future experiments should include chemokines, cytokines, and various
Int. J. Mol. Sci. 2020, 21, 6519 9 of 17
genes at different time points, namely 0, 4, 8, 12, 24, 48, and 72 h, to provide insights into which
components are being expressed or consumed and secreted by cells in response to LR-PRP and LP-PPP.
As previously mentioned, LR-PRP and LP-PRP, in which the numbers of platelets are similar would
clarify the effects of leukocytes more so than comparing LR-PRP and LP-PPP. Further studies that
adopt these recommendations would contribute to the development of targeted interventions aimed at
ECM diseases.
4. Materials and Methods
4.1. Samples
Whole blood, LR-PRP and LP-PPP residual samples were donated, to be used in these experiments,
by six females aged between 31 to 59 years undergoing an elective LR-PRP treatment unrelated to this
study. The donors complied with the physician’s health suitability criteria which excluded patients
with conditions listed in Table S3 of Supplementary Materials. Donors were referenced by assigned
numbers by the treating clinician. This research was approved by the Victoria University Human
Ethics Committee (Approval No. HRE18-041, Thursday, May 3rd, 2018).
4.2. Analysis of Leucocyte-Rich, Platelet-Rich Plasma and Leucocyte-Poor, Platelet-Poor Plasma
The Emcyte® PurePRP II manufacturer’s instructions were adhered to. Isolation, storage and
delivery of the blood samples were carried out according to the Good Manufacturing Practice Guidelines
and the Australian Regulatory Guidelines for Medical Devices (Therapeutics Goods Administration
Guideline, 2018). Samples of whole blood, LP-PPP and LR-PRP were immediately analysed by the
Dorevitch Pathology Clinical Trials laboratory (Western Health, Footscray Hospital, Melbourne, VIC,
Australia) for a complete data determination. The original 50 mL of whole blood was blended with
10 mL of sodium citrate, which equally diluted the whole blood, LR-PRP, and LP-PPP. For rigorous
reporting of data, the DEPA classification method was used to characterize all samples, which is based
on biological parameters that are classically used in the cell therapy field (described in Table S2) [18,43].
After the cell calculations were completed, the LR-PRP and LP-PPP were activated using 10% CaCl2 at
a volume ratio of 10:1 and then were incubated at 37 ◦C and 5% carbon dioxide for 1 h. The LR-PRP
and LP-PPP were centrifuged at 1900 g Force for 10 min to separate any clots. The LR-PRP and LP-PPP
were stored at −20 ◦C until required.
4.3. Cell Culture
The human caucasian foetal foreskin fibroblast cell line (HFFF2) (Cell Bank Australia) was used in
this study. The fibroblast cells were cultured in Dulbecco’s modified Eagle medium GlutaMAX™-1
media and supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco, Melbourne,
Australia) at 37 ◦C and 5% carbon dioxide. Fibroblasts were expanded and at the seventh passage,
all multiple cells in cryovials were frozen and stored in liquid nitrogen (cell bank) before being used.
4.4. Fibroblast Proliferation Method Using MTT
The effects of 5% LR-PRP and LP-PPP on human dermal fibroblasts were compared via a
colorimetric assay for assessing cell metabolic activity, namely MTT [96]. The 5% dose was established
according to the results of previous studies [68,70]. The MTT assay was performed on n = 3 samples,
and for each sample 6 replicate wells were used. Fibroblasts were seeded at a density of 1 × 103
cells/well in 96 U-shaped well culture plates and then incubated for 48 h to allow for adhesion in
complete medium of up to 80% confluence in order to prevent an artifactual decrease in proliferation.
The complete media was aspirated and replaced with serum-free media for 24 h in order to simulate
cell fibroblasts in chronic wounds [20]. The fibroblasts cells were evaluated as follows: (1) 5% LR-PRP;
(2) 5% LP-PPP; (3) serum-free media (negative control). Following intervention, the cells were incubated
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for 4, 8, 12, 24 and 48 h. The absorbance of each sample was measured at each time point at the optical
density of 570 nm using the BIO-RAD iMark microplate reader.
4.5. In Vitro Scratch Wound Assay
The in vitro scratch wound assay was utilized to determine directional cell migration based on
the observation of cell mobility into a scratch “wound” created in the fibroblast cell monolayer [68].
The assay was performed on n = 3 samples, and 6 replicate wells were used for each sample.
Human fibroblasts were seeded to a final density of 3 × 104 cells/well in 24-well microplates with
500 µL of complete media and incubated for 48 h to produce a maximally confluent monolayer.
The fibroblast samples were evaluated as follows: (1) 5% LR-PRP; (2) 5% LP-PPP; and (3) serum-free
media (negative control). After each scratch was created, the cells were washed with PBS. To measure
the cell mobility, the status of the scratch wound was monitored via the time lapse imaging system
BioStation IM-Q. Images were collected at time points of 0, 4, 8, 12, 24 and 48 h. All images were
uploaded into ImageJ (NIH, Bethesda, MD, USA), and their size was equally adjusted. A global scale
was set from a reference micrometre/micro-ruler image. The time of the image and length of the
wound were measured. The magnitude of the wound closure was measured and plotted against time.
The decreases of the scratch width over the 48 h period were calculated as the average distance between
the wound edges in µm. The wound area was calculated by tracing the cell-free area in captured
images. Wound closure and cell migration rates were calculated according to Grada, et al. [97].
Wound closure percentage (%) is the measurement of the fibroblast migration rate expressed as
the change in the wound area over 48 h divided by the change in wound width by the time spent
in migration.
Wound Closure % =
[
At = 0h − At = 4 h
At = 0h
]
× 100% (1)
At = 0 h is the area of the wound measured immediately after scratching (t = 0 h); At= 4 h is the
area of the wound measured hours after the scratch is performed. The cell migration rate equals the
change in wound width or closure divided by the time spent in migration; the closure percentage is
expected to increase as the cells migrated over the 48 h.
Hence, the Cell Migration formula is:
RM = (Wi −W f ) ÷ t (2)
(RM) = rate of cell migration (nm/h); Wi = initial wound width (nm); W f = final wound width
(nm); t = duration of migration in hours.
4.6. The Human ECM and Adhesion Molecules RT2 Profiler PCR Gene Array
The expression of genes was elucidated using the RT2 Profiler PCR Array for 84 human ECM
and cell adhesion genes (Qiagen, Chadstone, VIC, Australia). This array detects gene expressions that
encode human ECM proteins, including transmembrane receptors, adhesion molecules, E-cadherin,
ECM adhesion, basement membrane constituents, collagen, ECM structural constituents, ECM proteases
and protease inhibitors. The array contains a panel of 5 housekeeping genes used for normalisation of
data, plus a panel of three reverse transcription controls, a genomic DNA control and three positive
PCR controls.
In this experiment, human fibroblasts cells were seeded to a density of 3 × 106 cells in a 40 mL
flask containing 12 mL of complete media and incubated for 48 h to produce a confluent monolayer.
The fibroblasts were supplemented as follows: (1) 5% LR-PRP; (2) 5% LP-PPP; and (3) serum-free
media (negative control). Following 12 h incubation, fibroblast cells were extracted by standard
laboratory enzymatic methods [98]. Each cell pellet was individually collected for fibroblast mRNA
extraction using the RNAeasy mini kit (Qiagen) exactly according to the manufacturer’s instructions.
Thereafter, RNA samples were used to assess the RNA quality and concentration using Nanodrop
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(Denovix, Melbourne, Australia). The remaining RNA were aliquoted (6 µL RNA) into individual
0.5 mL micro-tubes for mRNA expression analysis according to the method previously described by
Dargahi [99].
4.7. Data Analysis Using Prism Programs and Qiagen Software Programs
The statistical analyses for the fibroblast proliferation and scratch wound assay were performed
using GraphPad Prism software, version 7.0e. Data were tested for normality and equal variance before
analysis. The 2-way ANOVA and Tukey’s multiple comparison tests were used with values of p < 0.05
being regarded as significant. Data are presented as mean ± SEM. To analyse the human ECM and
adhesion molecules RT2 Profiler PCR array the Qiagen software was used based on the −∆∆CT method
with normalisation of the raw data to 5 housekeeping genes, 1 DNA control, 3 reverse transcription
controls and 3 + PCR controls. Fold-change (2ˆ (−∆∆CT)) is the normalized gene expression (2ˆ(−∆CT))
in the test sample divided by the normalized gene expression (2ˆ (−∆CT)) in the control sample.
Fold-regulation represents fold-change results in a biologically meaningful way. Fold-change values
greater than 2 indicate a positive- or an up-regulation, and the fold-regulation is equal to the fold-change.
Fold-change values less than minus 2 indicate a negative or down-regulation, and the fold-regulation
is the negative inverse of the fold-change. The p values are calculated based on a Student’s t-test of the
replicate 2ˆ (−∆CT) values for each gene in the control group and treatment groups.
5. Conclusions
The present study provides indications of the ability of LR-PRP and LP-PPP to induce challenged
fibroblasts in vitro. This study did not include in vivo experiments and therefore may not be interpreted
to clinical applications. The fibroblast proliferation and wound scratch assay supported the hypothesis
in which the ability of LR-PRP to affect biological responses of fibroblasts did not exhibit catabolic
effects. The ECM and adhesion molecule expressions that we identified contribute to our scientific
understanding of the interplay and cross-talk between genes in the disassembly and reassembly of
the ECM during wound healing. These insights add knowledge to the rapidly expanding field of
ECM-driven diseases, particularly in the identification of underlying genetic bases and abnormal
pathways. Additionally, our results provide insight into how these genes respond to LR-PRP
and, by extension, other related autologous cell therapies. Overall, our findings suggest that high
concentrations of leucocytes and platelets demonstrate a stimulatory continuous anabolic and ergogenic
pathway on fibroblasts. Therefore, we propose that LR-PRP can be successfully employed to facilitate
wound healing.
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Abbreviations
ECM Extracellular matrix
ITG Integrin
ITGA Integrin alpha
ITGB4 Integrin beta 4
ITGAM Integrin alpha M chain
LP-PPP Leucocyte-poor, platelet poor plasma
LR-PRP Leucocyte-rich, platelet rich plasma
MMP Matrix metalloproteinase
MMP1 Matrix metallopeptidase 1 (interstitial collagenase)
MMP3 Matrix metallopeptidase (stromelysin 1, progelatinase)
MMP9 Matrix metallopeptidase (gelatinase, B.; 92kDa gelatinase, 92kDa type IV collagenase)
MMP11 Matrix metallopeptidase (stromelysin 3)
MMP12 Matrix metallopeptidase (macrophage elastase, metalloelastase)
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, a tetrazole
NCAM1 Neural cell adhesion molecule
PRP Platelet rich plasma
RBC Red blood cell
TIMP3 Tissue inhibitors of metalloproteinases
TGF-β Transforming growth factor beta
VCAM1 Vascular cell adhesion molecule 1
WBC White blood cell
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